Idorsia Ltd (CH:IDIA)
:IDIA
Want to see CH:IDIA full AI Analyst Report?
IDIA Stock Chart & Stats
CHF3.71
-CHF0.05(-3.98%)
At close: 4:00 PM EST
CHF3.71
-CHF0.05(-3.98%)
Day’s Range― - ―
52-Week RangeCHF1.80 - CHF4.87
Previous CloseN/A
Volume178.76K
Average Volume (3M)2.48M
Market Cap
CHF1.03B
Enterprise ValueCHF2.18B
Total Cash (Recent Filing)CHF94.70M
Total Debt (Recent Filing)CHF1.32B
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Jul 30, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding255,040,510
10 Day Avg. Volume2,649,008
30 Day Avg. Volume2,478,790
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF4.75Price Target Upside28.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.53
Revenue Forecast (FY)CHF227.22M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~90% gross margins indicate strong product-level economics and pricing power for Idorsia's marketed products. That margin profile provides a durable structural advantage: if operating expenses are reined in or sales scale resumes, high gross margins can translate into sustainable profitability and strong incremental cash conversion.
History Of Revenue Scale-upThe prior multi-year revenue expansion shows Idorsia can commercialize and scale a product from small base to meaningful sales, demonstrating commercial infrastructure and market access. This historical capability supports the company's ability to re-grow sales over 2–6 months if market demand or distribution recovers.
Commercialized Product (QUVIVIQ)Owning and marketing an approved, revenue-generating medicine provides recurring product sales, established distribution channels, and clinical/commercial infrastructure. This creates durable revenue optionality and partnership leverage versus pure research-stage peers, supporting medium-term commercial execution and licensing discussions.
Bears Say
Stressed Balance SheetDeeply negative equity and large debt relative to assets materially weaken financial flexibility and increase refinancing risk. Over the next several months this constrains Idorsia's ability to fund R&D or commercial expansion organically, raises interest burden risk, and could force dilutive or asset-sale solutions if cash needs persist.
Ongoing Cash BurnConsistent negative operating and free cash flow mean the company is consuming cash to run operations. This persistent cash burn forces reliance on external financing or partnerships, limiting strategic optionality. If negative cash flow persists, it will pressure runway and constrain investments in commercialization or late-stage programs.
Operating Losses & Revenue DropA steep TTM revenue decline alongside large operating losses indicates structural pressure on demand or execution. Persistent negative margins erode retained capital and make it harder to leverage strong gross margins. Continued declines threaten scalability of the business and increase probability of restructuring, partnership concessions, or financing needs.
IDIA FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest stock price was CHF1.80 and its highest was CHF4.87 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF1.03B.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Jul 30, 2026 which is in 54 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Apr 28, 2026. The company reported -CHF0.16 earnings per share for the quarter, beating the consensus estimate of -CHF0.185 by CHF0.025.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd pays a Notavailable dividend of CHF11.841 which represents an annual dividend yield of N/A. See more information on Idorsia Ltd dividends here
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.16.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 255,040,510 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.16 in its last earnings report, beating expectations of -CHF0.185. Following the earnings report the stock price went up 4.782%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in CH:IDIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
IDIA Stock 12 Month Forecast
Average Price Target
CHF4.75
▲(28.03% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Options Prices
Currently, No data available
---